#abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0